Viridian Therapeutics, Inc.
23.01-0.16 (-0.69%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · VRDN · USD
Key Stats
Market Cap
2.14BP/E (TTM)
-Basic EPS (TTM)
-3.57Dividend Yield
0%Recent Filings
8-K
Preliminary $490.9M cash balance
Viridian Therapeutics disclosed preliminary cash, cash equivalents, and marketable securities of $490.9 million as of September 30, 2025, on October 21, 2025, ahead of full Q3 financials. This unaudited figure, pending final closing procedures, signals robust liquidity for biotech operations. Yet it may shift materially. Strong cash position fuels pipeline progress.
8-K
Viridian secures $600M financing
Viridian Therapeutics inked a revenue rights deal with DRI Healthcare on October 17, 2025, netting up to $300 million upfront and milestone-based for veligrotug and VRDN-003, while committing tiered royalties on U.S. net sales starting at 7.5% up to $600 million. Simultaneously, it amended its loan agreement with Hercules Capital for a $300 million term loan facility, drawing $50 million initially at rates up to 9.45%, maturing October 17, 2030, to fuel clinical trials. This dual financing bolsters runway amid pivotal phase 3 studies. Yet royalties could climb if approvals lag.
10-Q
Q2 FY2025 results
Viridian Therapeutics posted a Q2 net loss of $100.7M, up 55% y/y from $65.0M, driven by R&D expenses surging 54% to $86.6M on clinical trial acceleration, while G&A rose 26% to $20.2M. Operating loss widened to $106.8M from $72.2M y/y, with net loss per common share at $(1.00) versus $(0.77), reconciled to 81.6M diluted shares. Cash burn hit $168.0M in operating activities for the half, offset by $175.8M from investment maturities, leaving $563.4M in cash and equivalents at quarter-end—enough for at least a year. No free cash flow disclosed, as capex was minimal at $0.1M. The Japan licensing deal with Kissei, inked post-quarter for $70M upfront plus milestones, bolsters liquidity. Yet clinical trials remain costly and risky.
8-K
Viridian's Q2 highlights veligrotug progress
Viridian Therapeutics reported Q2 2025 financials, highlighting veligrotug's Breakthrough Therapy Designation and 70% proptosis response durability at 52 weeks in the THRIVE trial, while advancing BLA submission for 2H 2025 and U.S. launch in 2026 if approved. The company inked an exclusive Japan license with Kissei for veligrotug and VRDN-003, netting $70 million upfront plus up to $315 million in milestones and royalties in the 20s to mid-30s. Cash stood at $563.4 million, funding operations into 2H 2027, yet R&D expenses jumped to $86.6 million from expanded trials. Momentum builds, but regulatory risks loom.
8-K
Viridian partners with Kissei for Japan
Viridian Therapeutics inked a collaboration and license deal with Kissei Pharmaceutical on July 30, 2025, granting exclusive rights to develop and commercialize veligrotug and VRDN-003—anti-IGF-1R antibodies for thyroid eye disease—in Japan. Viridian pockets a $70 million upfront payment, plus up to $315 million in milestones and tiered royalties from the twenties to mid-thirties on net sales. Kissei handles all Japan development, regulatory, and commercialization costs, while Viridian supplies the products. This partnership taps Kissei's rare disease expertise to accelerate access for Japanese patients, though milestone achievements hinge on regulatory and sales success.
IPO
Employees
Sector
Industry
DNTH
Dianthus Therapeutics, Inc.
33.82+0.15
LIANY
LianBio
0.07+0.00
MDGL
Madrigal Pharmaceuticals, Inc.
421.60-7.58
MRNA
Moderna, Inc.
24.70-0.65
REGN
Regeneron Pharmaceuticals, Inc.
652.91-1.57
TVRD
Tvardi Therapeutics, Inc.
4.78+0.06
VERA
Vera Therapeutics, Inc.
29.36-0.60
VIR
Vir Biotechnology, Inc.
5.91-0.52
VIRX
Viracta Therapeutics, Inc.
0.01+0.00
VRAX
Virax Biolabs Group Limited
0.60+0.01